- Structure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional American Depositary Shares
- Structure Therapeutics Announces Pricing of Upsized $476 Million Public Offering
- Structure Therapeutics Announces Proposed Public Offering of American Depositary Shares and Pre-Funded Warrants
- Structure Therapeutics Reports Positive Topline Data from its Phase 2a Obesity Study and Capsule to Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290
- Structure Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights
- Structure Therapeutics to Present at Leerink Partners Global Biopharma Conference
- Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Highlights
- Structure Therapeutics Provides Comprehensive GSBR-1290 Program Update Including Clinically Meaningful Proof-of-Concept Data From Phase 2a Clinical Study
- Structure Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights
- Structure Therapeutics Announces $300 Million Private Placement Equity Financing
More ▼
Key statistics
On Monday, Structure Therapeutics Inc (GPCR:NMQ) closed at 36.59, 43.10% above the 52 week low of 25.57 set on Aug 17, 2023.
52-week range
Open | 37.58 |
---|---|
High | 38.31 |
Low | 36.49 |
Bid | 36.61 |
Offer | 38.00 |
Previous close | 37.44 |
Average volume | 1.45m |
---|---|
Shares outstanding | 57.05m |
Free float | 45.86m |
P/E (TTM) | -- |
Market cap | 2.19bn USD |
EPS (TTM) | -2.32 USD |
Data delayed at least 15 minutes, as of Jul 22 2024 21:00 BST.
More ▼